Drugs / CVX-241
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01004822 | Mar 2010 → May 2014 | cancer | Pfizer | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVX-241 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01004822 ↗ |
| Known as | PF-05057459 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650388 ↗ |
| Modality | Protein / enzyme biologic | “A Phase 1, Multicenter, Open-label, Dose-escalation, Safety, Pharmacokinetic, And Pharmacodynamic Study Of Cvx-241, A Selective Angiopoietin-2 And Vascular Endothelial Growth...” NCT01004822 ↗ |